Author:
Shabbir Abdul Basit,Liaqat Mahrukh,Muhammad Atif Hafiz
Abstract
Hepatitis C virus (HCV) infection has long been a serious global public health concern; it is not only the main cause of end-stage liver disease, but it is also a leading source of liver cancer, but it also increases the risk of mortality from a variety of extrahepatic illnesses. Objective: The study's main objective is to see if successfully eradicating the Hepatitis-C virus with sofosbuvir-based antiviral therapy improves cirrhotic patients' quality of life. Methods: This cross-sectional study was conducted in Faisalabad Medical University from June 2019 to June 2020. The data was collected from 70 patients. The data was collected through a non-probability consecutive sampling technique. Results: The data were collected from 70 patients of both genders. We compared patients' quality of life. With sofosbuvir and ribavirin, 56 patients (79%) reached Sustained Virologic Response 12 (SVR12), Sofosbuvir, daclatasvir, and ribavirin were administered to 13 patients (18%), while sofosbuvir and ledipasvir were administered to two individuals (3%).Conclusions: Infection with chronic HCV, which is made worse by cirrhosis, has a major negative influence on the patient's physical, mental, social, and functional well-being, leading to a considerable reduction in their overall quality of life.
Publisher
CrossLinks International Publishers
Reference21 articles.
1. 1. Younossi ZM, Stepanova M, Younossi Z, Stepanova M, Feld J, et al. Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients with HCV Infection, With-out or with Compensated or Decompensated Cirrhosis. Clin Gastroenterol Hepatol. 2017,15(3):421-430.e6. doi: 10.1016/j.cgh.2016.10.037
2. 2. Nguyen DT, Tran TTT, Nghiem NM, Le PT, Vo QM, et al. Effectiveness of sofosbuvir based direct-acting antiviral regimens for chronic hepatitis C virus genotype 6 patients: Real-world experience in Vietnam. PLoS ONE 2020,15(5): e0233446. doi.org/10.1371/journal.pone.0233446
3. 3. Bourliere M, Gordon SC, Flamm SL, Cooper CL, Ramji A, et al. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. N Engl J Med. 2017,376(22):2134-46. doi.org/10.1056/NEJMoa1613512
4. 4. Li C, Yuan M, Lu L, Lu T, Xia W, et al. The genetic diversity and evolutionary history of hepatitis C virus in Vietnam. Virology. 2014,468-470:197-206. doi.org/10.1016/j.virol.2014.07.026
5. 5. Lai CL, Wong VW, Yuen MF, Yang JC, Knox SJ, et al. Sofosbuvir plus ribavirin for the treatment of patients with chronic genotype 1 or 6 hepatitis C virus infection in Hong Kong. Aliment Pharmacol Ther. 2016,43(1):96-101. doi.org/10.1111/apt.13429